A detailed history of Teacher Retirement System Of Texas transactions in Protagonist Therapeutics, Inc stock. As of the latest transaction made, Teacher Retirement System Of Texas holds 13,099 shares of PTGX stock, worth $506,538. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,099
Previous 11,032 18.74%
Holding current value
$506,538
Previous $495,000 2.22%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 11, 2025

BUY
$38.51 - $48.43 $79,600 - $100,104
2,067 Added 18.74%
13,099 $506,000
Q3 2024

Nov 13, 2024

BUY
$33.72 - $47.33 $48,084 - $67,492
1,426 Added 14.84%
11,032 $495,000
Q2 2024

Aug 09, 2024

SELL
$24.66 - $34.8 $16,374 - $23,107
-664 Reduced 6.47%
9,606 $333,000
Q1 2024

May 06, 2024

SELL
$21.79 - $32.15 $8,062 - $11,895
-370 Reduced 3.48%
10,270 $297,000
Q4 2023

Feb 07, 2024

SELL
$14.05 - $23.44 $32,511 - $54,240
-2,314 Reduced 17.86%
10,640 $244,000
Q3 2023

Oct 31, 2023

BUY
$16.68 - $23.66 $12,343 - $17,508
740 Added 6.06%
12,954 $216,000
Q2 2023

Jul 19, 2023

BUY
$18.02 - $29.36 $15,262 - $24,867
847 Added 7.45%
12,214 $337,000
Q1 2023

May 12, 2023

BUY
$10.78 - $25.38 $2,576 - $6,065
239 Added 2.15%
11,367 $261,000
Q4 2022

Feb 10, 2023

SELL
$7.36 - $11.17 $6,020 - $9,137
-818 Reduced 6.85%
11,128 $121,000
Q3 2022

Nov 03, 2022

BUY
$7.86 - $11.71 $93,895 - $139,887
11,946 New
11,946 $101,000
Q2 2022

Aug 09, 2022

SELL
$7.06 - $25.52 $63,024 - $227,817
-8,927 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$23.34 - $36.08 $10,806 - $16,705
463 Added 5.47%
8,927 $211,000
Q4 2021

Feb 10, 2022

BUY
$17.63 - $37.1 $149,220 - $314,014
8,464 New
8,464 $289,000

Others Institutions Holding PTGX

About Protagonist Therapeutics, Inc


  • Ticker PTGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,084,100
  • Market Cap $1.9B
  • Description
  • Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...
More about PTGX
Track This Portfolio

Track Teacher Retirement System Of Texas Portfolio

Follow Teacher Retirement System Of Texas and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Teacher Retirement System Of Texas, based on Form 13F filings with the SEC.

News

Stay updated on Teacher Retirement System Of Texas with notifications on news.